Is CVS Health (CVS) a risky stock?
As of July 21, 2026, Clavix grades CVS Health (CVS) C+ for risk, a composite score of 62 out of 100 on an A+ to F scale, which puts CVS in the "average" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind CVS's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how CVS scores on each, as of July 21, 2026.
What's moving CVS's risk right now
Company-specific signals Clavix flags behind CVS's current grade, drawn from recent news and filings as of July 21, 2026.
Caremark faces expanded regulatory constraints on formulary design and rebate practices, with mandated out-of-pocket caps on insulin and required net-cost-based patient pricing, w…
Investors evaluating CVS Health should weigh the seemingly high current valuation against forward earnings expectations, which may offer a more favorable entry point for those wit…
Pharmacy-focused sites to open in select communities to help increase access to pharmacy care Openings are part of ongoing commitment to serve communities and meet consumers where…
What a C+ grade means
On the Clavix A+ to F scale, CVS's composite of 62 falls in the C band (50–64), read as "average." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell CVS or any security. Grades are risk indicators, not predictions of return. Data may be delayed.